미국의 질브리스크(Zilbrysq) 시장 규모, 점유율, 동향 분석 보고서 : 적응증별, 유통 채널별, 부문 예측(2025-2030년)

U.S. Zilbrysq (Zilucoplan) Market Trends:

The U.S. Zilbrysq (Zilucoplan) market size was estimated at USD 60.61 million in 2024 and is projected to grow at a CAGR of 21.64% from 2025 to 2030. The U.S. Zilbrysq (Zilucoplan) industry is witnessing robust growth following its FDA approval in October 2023 for the treatment of anti-AChR antibody-positive generalized myasthenia gravis (gMG). The approval under orphan drug designation and priority review pathways has accelerated its entry into the U.S. neuromuscular therapeutics space, where demand for targeted, mechanism-based treatments continues to rise.

Zilbrysq's once-daily subcutaneous self-administration offers a compelling alternative to hospital-based intravenous complement inhibitors, supporting long-term disease management in both outpatient and home-care settings. Its differentiated profile has led to rapid adoption among neurologists treating refractory or corticosteroid-intolerant gMG patients. The presence of a well-established specialty pharmacy network, favorable commercial insurance coverage, and prescriber familiarity with complement pathway inhibition further strengthen Zilbrysq's early market trajectory. While gMG remains the only approved indication in the U.S. as of 2024, its patient-centric formulation and durable efficacy data continue to position the product competitively against both IV C5 inhibitors and emerging FcRn-targeted therapies.

Zilbrysq's focused label for anti-AChR antibody-positive generalized myasthenia gravis (gMG) provides a clear and differentiated commercial pathway in the U.S., where approximately 85% of diagnosed gMG patients test positive for AChR antibodies. The therapy's approval under orphan drug designation and priority review by the FDA underscores the high unmet need in this rare, chronic condition. In contrast to broad-spectrum immunosuppressants, Zilucoplan's selective inhibition of complement C5 directly targets the pathophysiologic cascade driving neuromuscular junction damage. This specificity is especially relevant in a treatment landscape increasingly oriented toward biologics with well-defined molecular targets. With gMG recognized as a lifelong condition requiring sustained control, Zilbrysq's targeted mechanism and regulatory protections support premium pricing and long-term payer alignment, solidifying its role in treatment sequencing.

The once-daily subcutaneous (SC) formulation of Zilucoplan provides a significant strategic advantage in the U.S. healthcare setting, where patients and payers are actively seeking alternatives to intravenous (IV) therapies that require frequent clinical visits. Unlike Soliris or Ultomiris-which are delivered via infusions administered in hospital or outpatient infusion centers-Zilbrysq can be self-injected at home using a prefilled syringe. This approach aligns with growing demand for decentralized chronic disease management, reducing infusion-related costs and improving treatment adherence. In the U.S., where specialty pharmacies dominate the distribution of rare disease biologics, Zilucoplan's SC format has enabled rapid integration into payer-preferred pharmacy networks and patient support programs, helping to mitigate initiation barriers and improve real-world outcomes. Its suitability for both commercial and Medicare populations further enhances uptake in a fragmented reimbursement landscape.

As of 2024, Zilbrysq faces limited direct competition in the U.S. for SC C5 complement inhibition, with no biosimilars in development and other approved C5 inhibitors-Soliris and Ultomiris-confined to intravenous administration. While newer FcRn inhibitors such as Vyvgart and Rozanolixizumab offer differentiated mechanisms, they do not overlap with the complement pathway and are often considered complementary rather than substitutive in refractory cases. This segmented competitive environment reduces therapeutic redundancy and supports market coexistence, allowing prescribers to tailor therapies based on individual patient profiles and response history. The lack of direct SC C5 competitors through at least 2030, combined with UCB's ongoing investments in real-world data collection and provider education, is expected to preserve Zilbrysq's clinical and economic moat in the U.S. rare neurology market.

U.S. Zilbrysq (Zilucoplan) Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Zilbrysq (Zilucoplan) market report based on indication, and distribution channel:

• Indication Outlook (Revenue, USD Million, 2018 - 2030)
• Generalized Myasthenia Gravis (gMG)
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Specialty Pharmacies
• Hospital/Institution-Based Pharmacies
• Home Healthcare Providers

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Zilbrysq (Zilucoplan) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
• 3.4. Pipeline Analysis
• 3.5. Patent Expiry Analysis
• 3.6. Pricing Analysis

Chapter 4. U.S. Zilbrysq (Zilucoplan) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Generalized Myasthenia Gravis (gMG)
  • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2018 - 2030 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Zilbrysq (Zilucoplan) Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2030
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Specialty Pharmacies
  • 5.4.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
• 5.5. Hospital/Institution-Based Pharmacies
  • 5.5.1. Hospital/Institution-Based Pharmacies Market, 2018 - 2030 (USD Million)
• 5.6. Home Healthcare Providers
  • 5.6.1. Home Healthcare Providers Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. UCB
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives

Chapter 7. Conclusion